Isogenic mutant human cells: A new tool for personalized cancer medicine

Cell Cycle

Volumn 9, Issue 1, 2010, Pages 20-21

  Di Nicolantonio, Federica ^a   Arena, Sabrina ^a   Gallicchio, Margherita ^b   Bardelli, Alberto ^a,c  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

BRAF; Cancer mutations; EGFR; Knock in; KRAS; Oncogenes; Pharmacogenomics; PIK3CA

Indexed keywords

B RAF KINASE; COMPLEMENTARY DNA; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA;

CELL FUNCTION; EDITORIAL; GENE FREQUENCY; GENE MUTATION; HUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 74549135338     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.1.10474     Document Type: Editorial

References (11)

1. Arena S, et al. Cancer Res 2007; 67:8468-76.
2. Konishi H, et al. Cancer Res 2007; 67:8460-7.
3. Samuels Y, et al. Cancer Cell 2005; 7:561-73.
4. Shirasawa S, et al. Science 1993; 260:85-8.
5. Yun J, et al. Science 2009; 325:1555-9.
6. Arena S, et al. Proc Natl Acad Sci USA 2007; 104:11412-7.
7. Sur S, et al. Proc Natl Acad Sci USA 2009; 106:3964-9.
8. Di Nicolantonio F, et al. Proc Natl Acad Sci USA 2008; 105:20864-9.
9. Hanahan D, et al. Cell 2000; 100:57-70.
10. Mani SA, et al. Cell 2008; 133:704-15.
11. Hahn WC, et al. Nature 1999; 400:464-8.